c-Myc modulation: a key role in melanoma drug response
Open Access
- 2 April 2015
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 16 (9) , 1375-1386
Abstract
Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells. We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment. For the first time, we reported c-myc modulation is critical for melanoma drug response. It appeared drug-specific and post-transcriptionally driven through PP2A; in correlation, cell pre-treatment with okadaic acid (OA), a specific PP2A inhibitor, as well as PP2A silencing of melanoma cells, was able to increase melanoma cell drug-sensitivity and c-myc protein level. This is relevant for designing efficacious therapeutic strategies in melanoma.Keywords
This publication has 38 references indexed in Scilit:
- Dabrafenib and its potential for the treatment of metastatic melanomaDrug Design, Development and Therapy, 2012
- A randomized phase 2 study of temozolomide and bevacizumab or nab‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanomaCancer, 2012
- Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cellsCarcinogenesis, 2012
- Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC OverexpressionPLOS ONE, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour TargetPLOS ONE, 2009
- Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxideLife Sciences, 2005
- The emerging role of reactive oxygen species in cancer therapyEuropean Journal of Cancer, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- An improved procedure for identifying and quantitating protein phosphatases in mammalian tissuesFEBS Letters, 1989